Senators grill industry groups over FDA user fee agreements to fund the agency through 2027
Members of the Senate health committee on Tuesday fired off questions at drug industry reps in the first of two hearings to deal with the latest five-year funding agreements that Congress has to re-authorize by the end of September and that the FDA relies on to review new drug, generic drug, biologic and biosimilar applications.
Committee Chair Patty Murray (D-WA) made clear in her opening remarks that the FDA has done a superior job, particularly when it’s come to the pandemic, living up to its “gold standard” tagline, but “FDA doesn’t run on gratitude.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
